InsightApr 8, 2026peer-reviewed · conference · specialty-lab
Blood biomarkers will reshape who gets diagnosed, and when
When the diagnostic test moves from PET scanner to phlebotomy chair, the population of "patients with a diagnosis" expands. The system is not yet sized for that expansion.
Plasma p-tau217 and related assays are crossing the threshold from research tool to clinical workflow — with consequences that extend well beyond convenience.
#diagnosis#biomarkers#access
InsightMar 30, 2026clinical-trial · industry-filing · peer-reviewed
The post-amyloid pipeline is a portfolio bet, not a successor
There will probably not be a single "next anti-amyloid." There will be three or four mechanisms that have to be combined and sequenced.
Tau, neuroinflammation, synaptic resilience, and metabolic mechanisms are advancing in parallel — and the most likely future is combination therapy, not displacement.
#pipeline#drug-development#treatment